Literature DB >> 29027642

Familial MPN Predisposition.

Tsewang Tashi1, Sabina Swierczek1, Josef T Prchal2.   

Abstract

Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been long speculated, but has not been clearly defined to date. Genome-wide association studies in family clusters of MPN have identified a number of genetic variants that are associated with increased germline risk for developing clonal MPN. The strongest association discovered so far is the presence of JAK2 46/1 haplotype, and subsequently, many studies have found additional variants in other genes, most notably in TERT gene. However, these still account for a small fraction of familial MPN, and more in-depth studies including whole genome sequencing are needed to gain better insight into familial genetic predisposition of clonal MPNs.

Entities:  

Keywords:  Family clusters; Germline predisposition; JAK2 46/1; JAK2 V617F; Myeloproliferative neoplasm

Mesh:

Substances:

Year:  2017        PMID: 29027642     DOI: 10.1007/s11899-017-0414-x

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  45 in total

1.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

Authors:  Damla Olcaydu; Ashot Harutyunyan; Roland Jäger; Tiina Berg; Bettina Gisslinger; Ingrid Pabinger; Heinz Gisslinger; Robert Kralovics
Journal:  Nat Genet       Date:  2009-03-15       Impact factor: 38.330

2.  TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Authors:  Angela G Fleischman; Karl J Aichberger; Samuel B Luty; Thomas G Bumm; Curtis L Petersen; Shirin Doratotaj; Kavin B Vasudevan; Dorian H LaTocha; Fei Yang; Richard D Press; Marc M Loriaux; Heike L Pahl; Richard T Silver; Anupriya Agarwal; Thomas O'Hare; Brian J Druker; Grover C Bagby; Michael W Deininger
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.

Authors:  Jelena D Milosevic Feenstra; Harini Nivarthi; Heinz Gisslinger; Emilie Leroy; Elisa Rumi; Ilyas Chachoua; Klaudia Bagienski; Blanka Kubesova; Daniela Pietra; Bettina Gisslinger; Chiara Milanesi; Roland Jäger; Doris Chen; Tiina Berg; Martin Schalling; Michael Schuster; Christoph Bock; Stefan N Constantinescu; Mario Cazzola; Robert Kralovics
Journal:  Blood       Date:  2015-09-30       Impact factor: 22.113

5.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

6.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

7.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

8.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Dirk R Larson; Christy Finke; Emnet A Wassie; Lisa Pieri; Naseema Gangat; Rajmonda Fjerza; Alem A Belachew; Terra L Lasho; Rhett P Ketterling; Curtis A Hanson; Alessandro Rambaldi; Guido Finazzi; Juergen Thiele; Tiziano Barbui; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

9.  Two clinical phenotypes in polycythemia vera.

Authors:  Jerry L Spivak; Michael Considine; Donna M Williams; Conover C Talbot; Ophelia Rogers; Alison R Moliterno; Chunfa Jie; Michael F Ochs
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

10.  Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

Authors:  Xénia Cabagnols; Fabrizia Favale; Florence Pasquier; Kahia Messaoudi; Jean Philippe Defour; Jean Christophe Ianotto; Christophe Marzac; Jean Pierre Le Couédic; Nathalie Droin; Ilyas Chachoua; Remi Favier; M'boyba Khadija Diop; Valérie Ugo; Nicole Casadevall; Najet Debili; Hana Raslova; Christine Bellanné-Chantelot; Stefan N Constantinescu; Olivier Bluteau; Isabelle Plo; William Vainchenker
Journal:  Blood       Date:  2015-10-08       Impact factor: 22.113

View more
  6 in total

Review 1.  Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil.

Authors:  Lambert Busque; Manuel Buscarlet; Luigina Mollica; Ross L Levine
Journal:  Stem Cells       Date:  2018-06-08       Impact factor: 6.277

2.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

Review 3.  Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML.

Authors:  Peter Valent; Wolfgang Kern; Gregor Hoermann; Jelena D Milosevic Feenstra; Karl Sotlar; Michael Pfeilstöcker; Ulrich Germing; Wolfgang R Sperr; Andreas Reiter; Dominik Wolf; Michel Arock; Torsten Haferlach; Hans-Peter Horny
Journal:  Int J Mol Sci       Date:  2019-02-12       Impact factor: 5.923

Review 4.  The Genetic Makeup of Myeloproliferative Neoplasms: Role of Germline Variants in Defining Disease Risk, Phenotypic Diversity and Outcome.

Authors:  Elena Masselli; Giulia Pozzi; Cecilia Carubbi; Marco Vitale
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

Review 5.  JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.

Authors:  Dania G Torres; Jhemerson Paes; Allyson G da Costa; Adriana Malheiro; George V Silva; Lucivana P de Souza Mourão; Andréa M Tarragô
Journal:  Biomolecules       Date:  2022-02-11

6.  Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.

Authors:  Matteo Giaccherini; Angelica Macauda; Nicola Sgherza; Juan Sainz; Federica Gemignani; Josè Manuel Sanchez Maldonado; Manuel Jurado; Francesca Tavano; Grzegorz Mazur; Andrés Jerez; Joanna Góra-Tybor; Aleksandra Gołos; Francisca Hernández Mohedo; Joaquin Martinez Lopez; Judit Várkonyi; Raffaele Spadano; Aleksandra Butrym; Federico Canzian; Daniele Campa
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.